Your Article Summary
See Latest Articles(Click the title below to leave the MDLinx Network and go to the Journal's Website)
Bone protective effect of simvastatin in experimental arthritis
Journal of Rheumatology, 05/09/08
Funk JL et al. - Inhibition of HMG-CoA reductase may be therapeutically useful in preserving periarticular bone in RA joints via suppression of inflammation-induced bone resorption.
Methods- Aim was to investigate whether simvastatin, a potent HMG-CoA reductase inhibitor, alters bone turnover in an animal model of RA
- Hydrolyzed simvastatin (20 mg/kg/day) was administered sc to female Lewis rats 4 days before or 8 days after induction of arthritis
- Effects of simvastatin (vs vehicle) on periarticular bone, assessed by BMD, biochemical markers of bone turnover, and joint histology, were determined
- Effects on joint swelling were assessed clinically and histologically
- Simvastatin prevented early and late joint inflammation in association with a decrease in articular macrophage influx
- Simvastatin suppressed bone destruction late in the course of disease, preserving periarticular BMD and preventing increases in periarticular osteoclasts and serum pyridinoline levels
- Had no effect on these measures in normal animals
- Osteocalcin levels, which were decreased in arthritic animals, were unaltered by statin treatment
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
Haematologica, 12/18/09
Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Journal of Clinical Oncology, 12/18/09
How do providers assess antihypertensive medication adherence in medical encounters?
Journal of General Internal Medicine, 12/18/09